Insmed (INSM)
(Delayed Data from NSDQ)
$74.50 USD
+0.07 (0.09%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $74.48 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
INSM 74.50 +0.07(0.09%)
Will INSM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INSM
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
Other News for INSM
Artisan Mid Cap Fund Q2 2024 Commentary
Russell rotation: YTD market capitalizations swelling for small-caps
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)